 <h1>Cobicistat / darunavir / emtricitabine / tenofovir alafenamide Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cobicistat/darunavir/emtricitabine/tenofovir alafenamide: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Warning: Post treatment acute exacerbation of hepatitis BSevere acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue darunavir/cobicistat/emtricitabine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cobicistat / darunavir / emtricitabine / tenofovir alafenamide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cobicistat / darunavir / emtricitabine / tenofovir alafenamide:</p><p>
<i>More common</i>
</p><ul>
<li>Rash</li>
</ul><p>
<i>Less Common</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blurred vision</li>
<li>chills</li>
<li>constipation</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>dry mouth</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>general tiredness and weakness</li>
<li>heavy jaw feeling</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>indigestion</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>light-colored stools</li>
<li>loosening of a tooth</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>nausea</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomachache</li>
<li>sweating</li>
<li>troubled breathing</li>
<li>unexplained weight loss</li>
<li>unusual tiredness or weakness</li>
<li>upper right abdominal pain</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Muscle cramps, spasms, or stiffness</li>
<li>swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cobicistat / darunavir / emtricitabine / tenofovir alafenamide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Abnormal dreams</li>
<li>belching</li>
<li>difficulty in moving</li>
<li>excess air or gas in the stomach or bowels</li>
<li>headache</li>
<li>heartburn</li>
<li>passing gas</li>
<li>redistribution or accumulation of body fat</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling of the breasts or breast soreness in both females and males</li>
<li>swollen joints</li>
<li>weight loss</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cobicistat / darunavir / emtricitabine / tenofovir alafenamide: oral tablet</i></p><h3>General</h3><p>In clinical trials, the most common side effects reported in therapy-naive patients were diarrhea, headache, rash, nausea, fatigue, and abdominal pain; in suppressed therapy-experienced patients, diarrhea, headache, arthralgia, abdominal pain, fatigue, and rash were reported most often.  This drug was discontinued due to side effects in 2% and up to 1% of therapy-naive and therapy-experienced patients, respectively.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 22.6%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, vomiting, nausea, abdominal discomfort, abdominal distension, dyspepsia, flatulence, elevated amylase</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute pancreatitis, increased pancreatic enzymes, elevated lipase<sup>[Ref]</sup></p><p>Elevated amylase (1.5 to less than 3 times the upper limit of normal [1.5 to less than 3 x ULN]: up to 4.2%; 3 to less than 5 x ULN: 0.4%; at least 5 x ULN: up to 0.3%) and lipase (greater than 1.5 to less than 3 x ULN: 0.3%; 1.5 to less than 3 x ULN: 0.4%; 3 to less than 5 x ULN: up to 0.4%; at least 5 x ULN: up to 0.3%) have been reported.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Elevated total cholesterol (up to 21%), elevated low-density lipoprotein (LDL) cholesterol</p>
<p><b>Common</b> (1% to 10%): Fatigue, asthenia, elevated triglycerides, lipid-lowering drug started</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevated alkaline phosphatase</p>
<p><b>Frequency not reported</b>: Elevated high-density lipoprotein (HDL), total cholesterol to HDL ratio increased</p>
<p></p>
<p>Darunavir-containing regimen:</p>
<p>-Frequency not reported: Asthenia</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased weight, increased blood lipids<sup>[Ref]</sup></p><p>Elevated total cholesterol (240 to less than 300 mg/dL [6.19 to less than 7.77 mmol/L]: up to 21%; at least 300 mg/dL [at least 7.77 mmol/L]: up to 3.7%), LDL cholesterol (160 to 189 mg/dL [4.12 to less than 4.9 mmol/L]: up to 15.6%; at least 190 mg/dL [at least 4.9 mmol/L]: up to 6.3%), triglycerides (301 to 500 mg/dL [greater than 3.42 to 5.7 mmol/L]: up to 7%; 501 to 1000 mg/dL [greater than 5.7 to 11.4 mmol/L]: up to 1.4%; greater than 1000 mg/dL [greater than 11.4 mmol/L]: less than 1%), and alkaline phosphatase (2.5 to less than 5 x ULN: up to 0.3%) have been reported.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Decreased bone mineral density (BMD) (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Myalgia, arthralgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Osteonecrosis</p>
<p></p>
<p>Darunavir-containing regimen:</p>
<p>-Postmarketing reports: Rhabdomyolysis (associated with coadministration with HMG-CoA reductase inhibitors)</p>
<p></p>
<p>HIV protease inhibitors:</p>
<p>-Rare (0.01% to 0.1%): Rhabdomyolysis</p>
<p>-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis<sup>[Ref]</sup></p><p>In therapy-naive patients, BMD decreases of at least 5% at the lumbar spine were reported in 16% of patients using this drug and 22% of patients using cobicistat-darunavir plus emtricitabine-tenofovir disoproxil fumarate (DF); BMD decreases of at least 7% at the femoral neck were reported in 2% of patients using this drug and 15% of patients using cobicistat-darunavir plus emtricitabine-tenofovir DF.  In boosted protease inhibitor and tenofovir DF-treated patients, BMD decreases of at least 5% at the lumbar spine were reported in 2% of patients using this drug and 9% of patients using cobicistat-darunavir plus emtricitabine-tenofovir DF; BMD decreases of at least 7% at the femoral neck were reported in no patients using this drug and 2% of patients using cobicistat-darunavir plus emtricitabine-tenofovir DF.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (included dermatitis, allergic dermatitis, erythema, photosensitivity reaction, rash, erythematous rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, pruritic rash, toxic skin eruption, urticaria; up to 12.7%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, urticaria</p>
<p><b>Uncommon</b> (0.1% to 1%): Angioedema, lipodystrophy</p>
<p></p>
<p>Darunavir-containing regimen:</p>
<p>-Rare (0.01% to 0.1%): Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)</p>
<p>-Frequency not reported: Severe skin reactions (included conditions accompanied by fever and/or transaminase elevations)</p>
<p>-Postmarketing reports: Toxic epidermal necrolysis, acute generalized exanthematous pustulosis, DRESS<sup>[Ref]</sup></p><p>Rash was commonly reported with darunavir; rashes were generally mild-to-moderate, often occurring within the first 4 weeks of therapy and resolving with continued use.  In trials in therapy-naive patients, 12.7% of those using this drug reported rash (most were grade 1) and 1.5% of patients discontinued therapy due to rash (1 due to rash and hypersensitivity).  In the trial in suppressed therapy-experienced patients, 5.1% of patients using this drug reported rash (most were grade 1) and no patients discontinued therapy due to rash.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 13.1%)</p>
<p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Elevated glucose levels/hyperglycemia (126 to 250 mg/dL [6.95 to less than 13.89 mmol/L]: up to 6.9%; 251 to 500 mg/dL [13.89 to less than 27.75 mmol/L]: up to 1%) have been reported.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated glucose levels/hyperglycemia, anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia</p>
<p></p>
<p>Darunavir-containing regimen:</p>
<p>-Frequency not reported: Anorexia</p>
<p>-Postmarketing reports: Redistribution of body fat</p>
<p></p>
<p>Emtricitabine and tenofovir DF:</p>
<p>-Frequency not reported: Lactic acidosis</p>
<p></p>
<p>HIV protease inhibitors:</p>
<p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased glucose, redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Elevated creatinine</p>
<p><b>Frequency not reported</b>: Decreased urine protein-to-creatinine ratio (UPCR)</p>
<p></p>
<p>Cobicistat:</p>
<p>-Frequency not reported: Increased serum creatinine</p>
<p></p>
<p>Tenofovir prodrugs:</p>
<p>-Frequency not reported: Renal impairment (including acute renal failure, Fanconi syndrome)<sup>[Ref]</sup></p><p>Elevated creatinine (greater than 1.3 to 1.8 x ULN [or increased greater than 0.3 mg/dL above baseline]: up to 5.4%; greater than 1.8 to less than 3.5 x ULN [or increased 1.5 to less than 2 x above baseline]: up to 0.3%; at least 3.5 x ULN [or increased at least 2 x above baseline]: less than 1%) has been reported.</p>
<p></p>
<p>In a trial in therapy-naive HIV-1-infected patients (median estimated glomerular filtration rate [eGFR] 119 mL/min at baseline), mean serum creatinine increased by 0.05 mg/dL from baseline to week 48; median serum creatinine was 0.9 mg/dL at baseline at 0.95 mg/dL at week 48.  Serum creatinine increased and eGFR (according to Cockcroft-Gault) decreased by week 2 of therapy and remained stable through 96 weeks; the median change in eGFR (according to Cockcroft-Gault) was -5.5 and -5.2 mL/min at 48 and 96 weeks, respectively.  Median UPCR was 47 mg/g at baseline and 30 mg/g at week 48.</p>
<p></p>
<p>In a trial in virologically-suppressed patients treated with an HIV protease inhibitor and tenofovir DF-containing regimen (mean eGFR 104 mL/min at baseline) who switched to this drug or who remained on initial regimen (mean eGFR 103 mL/min at baseline), mean serum creatinine was similar to baseline for both at week 48; median UPCR was 62 mg/g at baseline and 37 mg/g at week 48 in those who switched to this drug and 63 mg/g at baseline and 53 mg/g at week 48 in those who remained on initial regimen.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST, increased hepatic enzyme</p>
<p><b>Frequency not reported</b>: Acute hepatitis</p>
<p></p>
<p>Darunavir-containing regimen:</p>
<p>-Uncommon (0.1% to 1%): Acute hepatitis, cytolytic hepatitis</p>
<p>-Frequency not reported: Drug-induced hepatitis</p>
<p>-Postmarketing reports: Liver injury</p>
<p></p>
<p>Emtricitabine and/or tenofovir DF:</p>
<p>-Frequency not reported: Severe hepatomegaly with steatosis, severe acute exacerbations of hepatitis B, liver decompensation, liver failure<sup>[Ref]</sup></p><p>Elevated ALT (greater than 2.5 to less than 5 x ULN: up to 2.4%; 5 to less than 10 x ULN: up to 1.1%; at least 10 x ULN: up to 0.4%) and AST (greater than 2.5 to less than 5 x ULN: up to 1.6%; greater than 5 to less than 10 x ULN: up to 1.1%; at least 10 x ULN: up to 0.5%) have been reported.</p>
<p></p>
<p>Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients coinfected with HIV-1 and hepatitis B virus after discontinuation of products containing emtricitabine and/or tenofovir DF.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p>
<p></p>
<p>HIV protease inhibitors:</p>
<p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Abnormal dreams<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Immune reconstitution inflammatory syndrome</p>
<p></p>
<p>Darunavir-containing regimen:</p>
<p>-Frequency not reported: Immune reconstitution inflammatory syndrome</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Darunavir-containing regimen:</p>
<p>-Uncommon (0.1% to 1%): Gynecomastia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Symtuza (cobicistat/darunavir/emtricitabine/tenof)." Janssen Pharmaceuticals, Titusville, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What drugs are contained in the HIV treatment Symtuza?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about cobicistat / darunavir / emtricitabine / tenofovir alafenamide</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: antiviral combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Symtuza</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cobicistat / darunavir / emtricitabine / tenofovir alafenamide: oral tablet</i></p><h3>General</h3><p>In clinical trials, the most common side effects reported in therapy-naive patients were diarrhea, headache, rash, nausea, fatigue, and abdominal pain; in suppressed therapy-experienced patients, diarrhea, headache, arthralgia, abdominal pain, fatigue, and rash were reported most often.  This drug was discontinued due to side effects in 2% and up to 1% of therapy-naive and therapy-experienced patients, respectively.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 22.6%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, vomiting, nausea, abdominal discomfort, abdominal distension, dyspepsia, flatulence, elevated amylase</p><p><b>Uncommon</b> (0.1% to 1%): Acute pancreatitis, increased pancreatic enzymes, elevated lipase<sup>[Ref]</sup></p><p>Elevated amylase (1.5 to less than 3 times the upper limit of normal [1.5 to less than 3 x ULN]: up to 4.2%; 3 to less than 5 x ULN: 0.4%; at least 5 x ULN: up to 0.3%) and lipase (greater than 1.5 to less than 3 x ULN: 0.3%; 1.5 to less than 3 x ULN: 0.4%; 3 to less than 5 x ULN: up to 0.4%; at least 5 x ULN: up to 0.3%) have been reported.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Elevated total cholesterol (up to 21%), elevated low-density lipoprotein (LDL) cholesterol</p><p><b>Common</b> (1% to 10%): Fatigue, asthenia, elevated triglycerides, lipid-lowering drug started</p><p><b>Uncommon</b> (0.1% to 1%): Elevated alkaline phosphatase</p><p><b>Frequency not reported</b>: Elevated high-density lipoprotein (HDL), total cholesterol to HDL ratio increased</p><p></p><p>Darunavir-containing regimen:</p><p>-Frequency not reported: Asthenia</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased weight, increased blood lipids<sup>[Ref]</sup></p><p>Elevated total cholesterol (240 to less than 300 mg/dL [6.19 to less than 7.77 mmol/L]: up to 21%; at least 300 mg/dL [at least 7.77 mmol/L]: up to 3.7%), LDL cholesterol (160 to 189 mg/dL [4.12 to less than 4.9 mmol/L]: up to 15.6%; at least 190 mg/dL [at least 4.9 mmol/L]: up to 6.3%), triglycerides (301 to 500 mg/dL [greater than 3.42 to 5.7 mmol/L]: up to 7%; 501 to 1000 mg/dL [greater than 5.7 to 11.4 mmol/L]: up to 1.4%; greater than 1000 mg/dL [greater than 11.4 mmol/L]: less than 1%), and alkaline phosphatase (2.5 to less than 5 x ULN: up to 0.3%) have been reported.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Decreased bone mineral density (BMD) (up to 16%)</p><p><b>Common</b> (1% to 10%): Myalgia, arthralgia</p><p><b>Uncommon</b> (0.1% to 1%): Osteonecrosis</p><p></p><p>Darunavir-containing regimen:</p><p>-Postmarketing reports: Rhabdomyolysis (associated with coadministration with HMG-CoA reductase inhibitors)</p><p></p><p>HIV protease inhibitors:</p><p>-Rare (0.01% to 0.1%): Rhabdomyolysis</p><p>-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis<sup>[Ref]</sup></p><p>In therapy-naive patients, BMD decreases of at least 5% at the lumbar spine were reported in 16% of patients using this drug and 22% of patients using cobicistat-darunavir plus emtricitabine-tenofovir disoproxil fumarate (DF); BMD decreases of at least 7% at the femoral neck were reported in 2% of patients using this drug and 15% of patients using cobicistat-darunavir plus emtricitabine-tenofovir DF.  In boosted protease inhibitor and tenofovir DF-treated patients, BMD decreases of at least 5% at the lumbar spine were reported in 2% of patients using this drug and 9% of patients using cobicistat-darunavir plus emtricitabine-tenofovir DF; BMD decreases of at least 7% at the femoral neck were reported in no patients using this drug and 2% of patients using cobicistat-darunavir plus emtricitabine-tenofovir DF.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (included dermatitis, allergic dermatitis, erythema, photosensitivity reaction, rash, erythematous rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, pruritic rash, toxic skin eruption, urticaria; up to 12.7%)</p><p><b>Common</b> (1% to 10%): Pruritus, urticaria</p><p><b>Uncommon</b> (0.1% to 1%): Angioedema, lipodystrophy</p><p></p><p>Darunavir-containing regimen:</p><p>-Rare (0.01% to 0.1%): Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)</p><p>-Frequency not reported: Severe skin reactions (included conditions accompanied by fever and/or transaminase elevations)</p><p>-Postmarketing reports: Toxic epidermal necrolysis, acute generalized exanthematous pustulosis, DRESS<sup>[Ref]</sup></p><p>Rash was commonly reported with darunavir; rashes were generally mild-to-moderate, often occurring within the first 4 weeks of therapy and resolving with continued use.  In trials in therapy-naive patients, 12.7% of those using this drug reported rash (most were grade 1) and 1.5% of patients discontinued therapy due to rash (1 due to rash and hypersensitivity).  In the trial in suppressed therapy-experienced patients, 5.1% of patients using this drug reported rash (most were grade 1) and no patients discontinued therapy due to rash.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 13.1%)</p><p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Elevated glucose levels/hyperglycemia (126 to 250 mg/dL [6.95 to less than 13.89 mmol/L]: up to 6.9%; 251 to 500 mg/dL [13.89 to less than 27.75 mmol/L]: up to 1%) have been reported.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated glucose levels/hyperglycemia, anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia</p><p></p><p>Darunavir-containing regimen:</p><p>-Frequency not reported: Anorexia</p><p>-Postmarketing reports: Redistribution of body fat</p><p></p><p>Emtricitabine and tenofovir DF:</p><p>-Frequency not reported: Lactic acidosis</p><p></p><p>HIV protease inhibitors:</p><p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased glucose, redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Elevated creatinine</p><p><b>Frequency not reported</b>: Decreased urine protein-to-creatinine ratio (UPCR)</p><p></p><p>Cobicistat:</p><p>-Frequency not reported: Increased serum creatinine</p><p></p><p>Tenofovir prodrugs:</p><p>-Frequency not reported: Renal impairment (including acute renal failure, Fanconi syndrome)<sup>[Ref]</sup></p><p>Elevated creatinine (greater than 1.3 to 1.8 x ULN [or increased greater than 0.3 mg/dL above baseline]: up to 5.4%; greater than 1.8 to less than 3.5 x ULN [or increased 1.5 to less than 2 x above baseline]: up to 0.3%; at least 3.5 x ULN [or increased at least 2 x above baseline]: less than 1%) has been reported.</p><p></p><p>In a trial in therapy-naive HIV-1-infected patients (median estimated glomerular filtration rate [eGFR] 119 mL/min at baseline), mean serum creatinine increased by 0.05 mg/dL from baseline to week 48; median serum creatinine was 0.9 mg/dL at baseline at 0.95 mg/dL at week 48.  Serum creatinine increased and eGFR (according to Cockcroft-Gault) decreased by week 2 of therapy and remained stable through 96 weeks; the median change in eGFR (according to Cockcroft-Gault) was -5.5 and -5.2 mL/min at 48 and 96 weeks, respectively.  Median UPCR was 47 mg/g at baseline and 30 mg/g at week 48.</p><p></p><p>In a trial in virologically-suppressed patients treated with an HIV protease inhibitor and tenofovir DF-containing regimen (mean eGFR 104 mL/min at baseline) who switched to this drug or who remained on initial regimen (mean eGFR 103 mL/min at baseline), mean serum creatinine was similar to baseline for both at week 48; median UPCR was 62 mg/g at baseline and 37 mg/g at week 48 in those who switched to this drug and 63 mg/g at baseline and 53 mg/g at week 48 in those who remained on initial regimen.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST, increased hepatic enzyme</p><p><b>Frequency not reported</b>: Acute hepatitis</p><p></p><p>Darunavir-containing regimen:</p><p>-Uncommon (0.1% to 1%): Acute hepatitis, cytolytic hepatitis</p><p>-Frequency not reported: Drug-induced hepatitis</p><p>-Postmarketing reports: Liver injury</p><p></p><p>Emtricitabine and/or tenofovir DF:</p><p>-Frequency not reported: Severe hepatomegaly with steatosis, severe acute exacerbations of hepatitis B, liver decompensation, liver failure<sup>[Ref]</sup></p><p>Elevated ALT (greater than 2.5 to less than 5 x ULN: up to 2.4%; 5 to less than 10 x ULN: up to 1.1%; at least 10 x ULN: up to 0.4%) and AST (greater than 2.5 to less than 5 x ULN: up to 1.6%; greater than 5 to less than 10 x ULN: up to 1.1%; at least 10 x ULN: up to 0.5%) have been reported.</p><p></p><p>Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients coinfected with HIV-1 and hepatitis B virus after discontinuation of products containing emtricitabine and/or tenofovir DF.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p><p></p><p>HIV protease inhibitors:</p><p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Abnormal dreams<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Immune reconstitution inflammatory syndrome</p><p></p><p>Darunavir-containing regimen:</p><p>-Frequency not reported: Immune reconstitution inflammatory syndrome</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Darunavir-containing regimen:</p><p>-Uncommon (0.1% to 1%): Gynecomastia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Symtuza (cobicistat/darunavir/emtricitabine/tenof)." Janssen Pharmaceuticals, Titusville, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What drugs are contained in the HIV treatment Symtuza?</li>
</ul><h2>More about cobicistat / darunavir / emtricitabine / tenofovir alafenamide</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: antiviral combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>